Drug Trial Radar · NCT05983783
Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the mHSPC
Last checked: Nov 19, 2026Latest source record: Aug 9, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Aug 1, 2023
Primary completion
Dec 31, 2025
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- The First Affiliated Hospital with Nanjing Medical UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 9, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 40 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Evaluate whether the combination of Rezvilutamide and androgen deprivation therapy (ADT) with docetaxel improves overall survival (OS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) compared to the combination of Rezvilutamide and ADT.
Conditions
- Metastatic Prostate Cancer
- Hormone Sensitive Prostate Cancer
- Chemotherapy Effect
Interventions
DocetaxelDrug
This is Triple drug regimen for mHSPC
RezvilutamideDrug
This is doubling drug regimen for mHSPC
Primary outcomes
What the sponsor says the trial is designed to measure.
- rPFSTime frame: 36 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Urology dpt, First Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.